First annual meeting of the Association of Cancer Physicians (in conjunction with the 27th AGM of the British Association for Cancer Research). March 24-26, 1986, Bristol, UK. Abstracts. by unknown
Br. J. Cancer (1986), 54, 199-221
First Annual Meeting of the Association of Cancer
Physicians*
(In conjunction with the 27th AGM of the British Association for Cancer
Research) March 24-25, 1986
Held at the University ofBristol, UK.
Abstracts of members' proffered paperst
High dose hydroxyurea as a DNA repair inhibitor:
A phase I and II study in lung cancer
D. Veale, B.J.M. Cantwell, N. Kerr, A. Upfold,
M. Earnshaw & A.L. Harris
Clinical.Oncology and Pharmaceutical Quality
Control Laboratory, Newcastle General Hospital,
Newcastle upon Tyne, UK.
Hydroxyurea (HO) is an S-phase cell-cycle-specific
agent that selectively inhibits DNA synthesis, by
inhibition of ribonucleotide reductase. HO concen-
trations >1 mm inhibit DNA synthesis by >99%
in human lung cancer lines in vitro. Concentrations
between 1 and 10mm inhibit DNA repair. We
conducted a phase 1 trial to achieve levels > 1 mM
with the aim of using hydroxyurea as a repair
inhibitor and to assess duration for which this
could be maintained without marrow and tissue
toxicity. Seventeen patients with advanced non-
small cell lung cancer were given HO 1 gh- by i.v.
infusion or 6G hourly p.o. to a dose of 24g/24h
n=7, 32g/32h n= 1, 36g/36h n=26, 48g/48h
n=9. There was no marrow toxicity at 24h, 2
WHO grade 1, 1 grade 2 at 36h and 1 grade 3
plus 1 grade 2 at 48h. Five patients had some
nausea and vomiting and 1 had mucositis. Two
patients showed evidence of radiological response
after three courses of treatment, and three had
evidence of static disease. Serum HO levels were
monitored in 26 i.v. and in 5 oral courses of
treatment. Serum level of >1 mm was maintained
from 6h. There was a small variation in levels
achieved (s.e. 5% ofthe mean area under the curve).
Thus we have shown that HO can be given by
infusion for 48h to achieve a serum concentration
*Enquiries to the ACP Secretariat, Department of
Medical Oncology, Christie Hospital and Holt Radium
Institute, Manchester M20 9BX, UK.
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above 1 mm. This regimen could be used for DNA
repair inhibition and potentiation of other drugs
A randomised trial to evaluate the effect of schedule
on the activity of etoposide in small cell lung cancer
M.L. Slevin, P.I. Clark, M. Richards, R.J. Osborne,
S. Malik, C.D. Wood, V.J. Harvey, S.P. Joel,
J.S. Malpas & P.F.M. Wrigley
ICRF Department ofMedical Oncology, St
Bartholomew's and Hackney Hospitals, London, UK.
The activity of two different schedules of etoposide
in small cell lung cancer (SCLC) has been investi-
gated. Forty patients (pts) with previously untreated
extensive SCLC were randomised to receive single
agent etoposide 500mgm 2 either as a 24h
infusion, or as 5 daily doses of lOOmgm-2 given as
an infusion over 2h. It was shown that etoposide is
stable in solution for 24h. Both regimes were
repeated every 21 days for 6 cycles. At relapse pts
with a Karnofsky performance score of 60 or more
received a combination of cyclophosphamide
(750mgm 2), vincristine (2mg) and adriamycin
(50mgm-2), whilst those with a score of 50 or less
received radiotherapy or other symptomatic treat-
ment. The same therapy was used at relapse in both
arms of the study.
Thirty-eight patients are currently evaluable. The
two groups were equal as regards Karnofsky
performance status, number of metastatic sites,
bone marrow involvement, albumin and serum
sodium.
Results Evaluable Partial Complete Median
patients response response survival
24h infusions 20 2 (10%) 0 167 days
5 daily doses 18 14 (78%) 0 294 days
©¢) The Macmillan Press Ltd., 1986
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The partial response rate was significantly greater
in the 5 day schedule (P= <0.0001) as was median
survival (P=0.03). Treatment was well tolerated
with few side effects in either arm. Bone marrow
toxicity was mild. Etoposide pharmacokinetics were
measured in all pts and the total areas under the
curve were equivalent in both arms. This study
demonstrates that a 5 day schedule of etoposide is
clearly superior to a 24h schedule in SCLC.
High dose carboplatin (JM8) in patients with lung
cancer: A phase I study
M.E. Gore, A.H. Calvert & I.E. Smith
Lung Unit, Royal Marsden Hospital, Downs Road,
Sutton, Surrey, UK.
Carboplatin (JM8) is an active analogue of cis-
platin in small cell lung cancer. Its main advantage
is that it is without the nephro-, neuro- and oto-
toxicity of its parent compound cis-platin. In
conventional dosage (400mgm-2 i.v. q. 28 days) the
dose limiting toxicity of JM8 is myelosuppression.
We have investigated the feasibility of giving high
doses of JM8 and have treated 5 patients at
800 mgm-2 (9 courses), 4 patients at 1.2gm-2 (5
courses) and 4 patients at 1.6gm-2 (5 courses).
Seven patients had small cell lung cancer (SCLC)
and 6 had non-small cell lung cancer. Sixteen
courses were evaluable and myelosuppression was
the major toxicity. At 1.2gm-2 the white cell count
(WCC) fell below 2 x 10 1-1 on day 9 for 7 days,
the nadir was 0.8 x 109 1 on day 14, the platelet
count fell below 100 x 1091-1 on day 8 for 9 days,
nadir 17 x 1091-1 on day 14. At 1.6gm-2 the
WCC fell below 2 x 109 1 on day 8 for 6 days,
nadir 0.7 x 1091- on day 12, and the platelets fell
below 100 x 1091-1 on day 9 for 11 days, nadir
12x 1091-1 on day 14. Treatment was well
tolerated with only 2 patients developing lethargy
and malaise for 6 days after treatment at 1.2g and
1.6gm 2. Significant peripheral neuropathy or
oto-toxicity was not seen but 1 patient developed
alopecia severe enough to require a wig. Cumulative
myelotoxicity did not seem to occur at any dose
level. EDTA clearances, however, fell in 5/11
evaluable patients by >25% but never >50%.
Five patients with SCLC achieved either complete
remission (2) or partial remission (3). High dose
JM8 up to 1600 mm-2 is feasible, well tolerated,
does not require autologous bone marrow
transplantation and appears very active against
SCLC.
A new thymidylate synthase (TS) inhibitor, CB3717,
in human primary liver cancer (PLC): In vitro,
xenograft and phase II studies
M.F. Bassendine, A.L. Harris, N. Curtin
& 0. James
Departments ofMedicine, Clinical Oncology &
Cancer Research Unit, University ofNewcastle upon
Tyne, UK.
PLC is the commonest tumour world-wide but
there is a lack of effective drugs. Because of high
TS activity and rapid thymidine breakdown in
some hepatomas, TS is a rational target for
therapy. We have investigated a new TS inhibitor,
CB3717, in 2 human PLC cell lines (PLC/PRF/5,
HEP3B/NU71) in vitro, the ID50 for CB3717 was
2-3,m, a level of achieved in vivo with 300mgm 2
i.v. The lines were grown as xenografts and both
were inhibited by CB3717. These lines appeared
more sensitive than some other xenografts. The
activity of CB3717 led to a phase II trial. Fourteen
patients with histologically proven PLC were
treated with 300mgm 2 i.v. every 3 weeks. There
were 8 men, 6 women, age 27-74 years, mean
56 years; 11 had cirrhosis. Six were grade A (ex-
pected survival>14/52), 8 were grade B (expected
survival < 14/52). There were 6 responders with
>50% reduction in FP and 3 of these had greater
than a 1 log fall in FP. Five of 6 responders were
female. The median survival of non-responders was
1 month, responders 13 months, 4 still alive. TS
inhibition is an effective target in hepatoma and
ways to enhance this are being studied.
The effect of verapamil on the pharmacokinetics of
adriamycin
D. Kerr', J. Graham', J. Cummings',
G. Morrison', M.J. Brodie2 & S.B. Kaye1
Departments of'Medical Oncology and 2Medicine,
University ofGlasgow, Glasgow, UK.
Evidence from a wide range of experimental
tumour systems indicates that the calcium channel
blocker verapamil can enhance the cytotoxic
efficacy of adriamycin, thereby circumventing
resistance to this drug, and several phase I clinical
studies of the combination of the 2 drugs have been
initiated. Since adriamycin undergoes extensive
hepatic metabolism, and verapamil increases hepatic
blood flow and inhibits the hepatic microsomal
enzyme system, there is the potential for a major
pharmacological interaction between these 2 drugsACP 1st ANNUAL MEETING 201
in clinical practice. To investigate this we have
examined the influence of verapamil on the kinetics
of adriamycin in patients with small cell lung
cancer. Five patients were treated with combina-
tion chemotherapy comprising adriamycin, cyclo-
phosphamide, vincristine and VP16. Oral verapamil
(80mg TDS for 3 days followed by 120mg QDS
for 4 days) was given with one or other of the
first 2 courses of chemotherapy, in random order.
Adriamycin and verapamil were measured by
sensitive and specific HPLC techniques based on
fluorescence detection. Combined treatment with
verapamil increased peak levels of adriamycin
(2289+1243 vs 1122+898ngml-1), the terminal
1/2-life (36+12 vs 23.2+6.8h), and steady state
vol. of distribution (1360+950 vs 998+10001),
whereas the vol. of central compartment (16.8 + 14
vs 31.4+251) and plasma clearance (36+ 18 vs
46+ 161h-1) were reduced. Adriamycinol and 7-
deoxyaglycone metabolite levels were similar in
both groups. Steady state verapamil levels ranged
from 80-110ngml-1. It would appear from this
preliminary study that there is a significant pharma-
cokinetic interaction between adriamycin and
verapamil which could result in enhanced activity.
Nabilone, prochlorperazine and dexamethasone -
good antiemetic control with few side effects
G.J. Forrest', D. Cunningham', A. Hutcheon2,
R. Moss', T. Young' & M. Soukopl
'Department ofMedical Oncology, Royal Infirmary,
Glasgow and 2Department ofClinical Oncology,
Royal Infirmary, Aberdeen, UK.
Our previous experience has shown nabilone (2mg)
and prochlorperazine (5mg) to be a useful
combination in controlling chemotherapy induced
emesis. However, at these doses drowsiness and
xerostomia were quite frequent and dysphoria
occurred occasionally. We have, therefore, per-
formed a double blind crossover study comparing
nabilone 1 mg (N) and prochlorperazine 5mg (P)
given at least 2h prior to therapy and again at
10pm on the evening oftherapy, with N, P and 20mg
dexamethasone (D) given i.v. with therapy. Sixty-
three patients receiving chemotherapy without cis-
platin have entered the study with 57 patients
completing the crossover. With N+P+D there was
complete control of vomiting in 67% of patients
which was significantly better (P<0.01) than N+P
alone. Side effects were infrequent or mild and only
5% of patients experience severe sedation. No
patient reported dysphoria. There was a significant
patient preference (P<0.01) for the dexamethasone
containing arm.
This study demonstrates that dexamethasone
contributes significantly to the emetic control of
nabilone and prochlorperazine, and has also
confirmed the abolition of CNS side effects of
nabilone when this drug is combined with
prochlorperazine.
Fertility after chemotherapy for male and female
germ cell tumours
D. Pektasides, G.J.S. Rustin, K.D. Bagshawe,
E.S. Newlands & R.H.J. Begent
Department ofMedical Oncology, Cancer Research
Campaign Laboratories, Charing Cross Hospital,
London W6, UK.
Gonadal function was assessed in 59 men and 31
women who successfully completed chemotherapy
with the POMB/ACE regimen (Newlands et al.,
Lancet, i, 948, 1983) for germ cell tumours.
Spermatogenesis had recovered in 29 (49%) of the
men from 24-84 months after completion of
treatment. None of the 11 men who received para-
aortic radiotherapy in addition to chemotherapy
recovered spermatogenesis. Other factors that were
associated with permanent sterility included original
tumour bulk >5cm diameter (P=0.011), and
duration of chemotherapy .6 months (P=0.029).
Seventeen (81%) of the 21 patients without these
adverse factors recovered spermatogenesis compared
with 12 (32%) of 38 patients who had one or more
ofthese factors. There was no significant correlation
between azoospermia or oligospermia prior to
chemotherapy, age .25 or >30, or laparotomy
during treatment, and recovery of spermatogenesis.
Menstruation was not expected, at the time of
analysis, after chemotherapy in 15 of the 31 women
because of the extent of surgery in 11, young age in
3, pelvic radiotherapy in 1, 46xy karyotype in 1 and
only 3 month period off chemotherapy in 1. All the
remaining women whose median age at start of
chemotherapy was 21 years (9-38) are now mens-
truating. Three of these women have so far had
successful pregnancies and 9 of the men have
fathered children. There have been no congenital
abnormalities.202 ACP 1st ANNUAL MEETING
Gastric adenocarcinoma: Does chemotherapy improve
survival?
D. Cunninghan1, D. Hole3, D.J. Taggart2,
D.C. Carter2, M. Soukop' & C.S. McArdle2
'Department ofMedical Oncology and 2University
Department ofSurgery, Glasgow Royal Infirmary
and 3the Cancer Surveillance Unit, Ruchill Hospital,
Glasgow, UK.
In our experience only 11% of patients with gastric
cancer survive 5 years. All long term survivors are
'surgical cures'. Chemotherapy is palliative and its
effect on overall survival is unknown.
Using Cox's Regression Model, we have analysed
the impact of chemotherapy on the survival of
202 patients with advanced gastric cancer treated
between 1974-1984 in Glasgow Royal Infirmary.
The adjusted median survival (160 days) of
patients (n =50) receiving chemotherapy (usually
FAM) was significantly better (P= <0.001) than
those who did not (n= 152), median survival 71
days. However, when deaths occurring within the
first 14 days after diagnosis were excluded, the
significant value dropped to P=0.02 which pre-
sumably reflects the patient selection for chemo-
therapy. Moreover, comparison of groups from the
period 1974-1979 when 8% received chemotherapy
(n=92) with equivalent groups from the period
1980-1984 when 45% of patients received chemo-
therapy (n= 110) showed no significant improvement
for patients treated with chemotherapy.
The failure to show a major improvement in
survival following chemotherapy is a measure of the
lack of activity of regimens such as FAM in the
majority of patients with gastric cancer and
underlines the need to continue to investigate new
chemotherapy protocols.
Weekly EMA/CO chemotherapy for high risk
gestational trophoblastic tumours (GTTs)
E.S. Newlands, G.J.S. Rustin, K.D. Bagshawe,
R.H.J. Begent & L. Holden
Cancer Research Campaign Laboratories, Charing
Cross Hospital, London W6, UK.
The development of drug resistance remains a
problem in patients with high risk GTTs with
adverse prognostic factors (Bagshawe, Cancer, 38,
1373, 1976). To minimise this, we have developed a
weekly schedule of chemotherapy. Sixty-five
patients in the high risk group of GTTs who were
clearly evaluable for response were treated with
etoposide 100mgm-2 day I and 2, methotrexate
100mgm-2 bolus and 200 mgm-2 12h infusion
day 1, actinomycin D 0.5mgday 1 and 2 (EMA);
repeated day 15 etc. Vincristine l.0mgm-2, cyclo-
phosphamide 600mgm 2 (C) day 8; repeated day
22 etc. Thirty-three of 65 (51%) of patients had
received no prior chemotherapy; 32/65 (49%) had
demonstrated drug resistance to prior chemo-
therapy. Complete response (CR) defined as hCG
concentrations falling until 3 successive values were
undetectable (<2,u1-1) was achieved in 27 (82%) of
those with no prior treatment and 23 (72%) of
those who had received prior chemotherapy.
Currently 30 (91%) of those with no prior
treatment are alive NED (follow-up 2-62 months,
median 32); one died early from pulmonary insuffi-
ciency; one died from drug resistance and one died
from myeloid leukaemia 15 months off treatment.
Twenty-five (78%) of those with prior treatment
are alive NED (follow-up 2-59 months, median 35)
and 7 died from drug resistance. Haematological
toxicity (WHO) was haemoglobin grade 4
(<6.5g/100ml): 1.5%; grade 3: 40.6%; grade 2:
40.2%; white cell count grade 4 (<lx l091-1):
15.9%; grade 3: 43.4%; grade 2: 27.5%; platelets
grade 4 (<25xl09l1-): 1.5%; grade 3: 4.4%;
grade 2: 7.3%. In addition, of 25 patients who
could not be assessed for response or were treated
with a combination where adriamycin replaced
vincristine (9 patients), 22 (88%) are alive NED,
giving a total overall survival of 77/90 (86%).
Subjective toxicity has been less than with our
previous chemotherapy (CHAMOCA) in high risk
patients.
A controlled trial of adjuvant chemotherapy with an
adriamycin-based regimen (AVCMF) for carcinoma
of the breast
A. Howell, J.M. Morrison, R.J. Grieve,
I.J. Monypenny, K. Kelly & J.A. Waterhouse
CRC West Midlands Clinical Trials Centre, Queen
Elizabeth Hospital, Edgbaston, Birmingham and
CRC Department ofMedical Oncology, Christie
Hospital, Wilmslow Road, Manchester, UK.
A multicentre regional trial of adjuvant
chemotherapy was initiated in 1976. Patients with
positive axillary nodes (n=540) were randomised,
after simple mastectomy, to receive no further
treatment (n=263) or 8 cycles of chemotherapy
(n =277). The regimen was given over 18 h and
consisted of adriamycin 50mg i.v. and vincristine
1 mg i.v. at time zero, followed by cyclo-
phosphamide 250mg i.v. at 6h at which time aACP Ist ANNUAL MEETING 203
12h infusion ofmethotrexate was started. Fluouracil
250mg i.v. and Folinic Acid (FA) 15mg i.v.
were given at 18h followed by FA 15mg 6
hourly x 3 p.o. At least 77% of patients received 8
cycles and 86% at least 4 cycles of therapy. There
were no dosage reductions. This analysis is of
August 1985. In the control group 179/263 (68%)
have recurred and 116/262 (42%) have died. In the
treated group 157/277 (57%) have recurred and
109/277 (41%) have died. The relapse free survival
was prolonged in treated patients overall (P=0.001)
and in patients <50 years, P=0.005 and >50 years
P=0.009. There was no survival advantage overall,
or for patients below or over 50 years. There were
no treatment-induced deaths or episodes of cardiac
failure. We conclude that this chemotherapy delays
relapse but at this stage of follow-up is not
associated with a survival advantage.
Vincristine, adriamycin and cyclophosphamide
chemotherapy followed by radiotherapy and surgery
in the treatment of locally advanced breast cancer
I.R. Campbell', J.A. Green1, R.D. Erringtont,
H.M. Warenius1 & S.J. Leinster2
'Department ofRadiation Oncology, Clatterbridge
Hospital, Bebington, Wirral and 2Department of
Surgery, Royal Liverpool Hospital, Liverpool, UK.
Locally advanced breast cancer (T3, T4, N2, N3)
presents a difficult management problem. Combined
modality treatment has been proposed to improve
on the poor rate of local control achieved by
surgery or radiotherapy alone (Kantarjian et al.,
Eur. J. Clin. Oncol., 20, 1353, 1984). We report
the results of our policy of sequential chemo-
therapy and radiotherapy given to 37 patients. A
trial of hormone therapy had been given in 25%
of patients, but no patient had previous exposure
to chemotherapy or radiotherapy. VAC combination
chemotherapy(vincristine 1.4mgm 2 i.v., adriamycin
50 mgm-2 i.v. and cyclophosphamide 600 mgm-2
i.v.) was given every 21 days for 3 to 6 cycles.
Toxicity was primarily nausea, vomiting and alopecia
but no patients discontinued treatment for this
reason. Following chemotherapy surgical excision of
residual masses was performed where appropriate.
Subsequently, consolidation radiotherapy was given
to most patients (45Gy in 18 fractions with a 9Gy
boost to the axilla and a 12Gy boost to the
primary site). Of 24 evaluable patients, 15 (70%)
responded to the initial VAC chemotherapy with
complete remission in 4 patients. With the addition
of radiotherapy and/or surgery, the response rate
increased to 80%, with 15 patients (63%) achieving
a complete remission. In these complete responders
the relapse free survival was 48% at 2 years.
We conclude that 3-6 courses of VAC chemo-
therapy combined with surgery and radical radio-
therapy provides a rapid and effective method of
achieving control in locally advanced breast cancer.
Treatment of hypercalcaemia secondary to metastatic
breast cancer with 3 amino-1, 1-hydroxypropylidene
biphosphonate (APD)
R.E. Coleman & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital,
London SE] 9RT, UK.
Hypercalcaemia is a relatively common
complication of metastatic breast cancer caused
primarily by osteolytic bone destruction. Estab-
lished treatment consists of intravenous saline to
reverse the deterioration in glomerular filtration
and inhibition of osteoclast function. We have
studied the osteoclast inhibitor APD to confirm the
efficacy of this drug and investigate the dose-
response relationship.
Eighteen consecutive patients with metastatic
breast cancer and hypercalcaemia (median
3.2mmoll-1) have been studied. All patients were
rehydrated with 0.9% saline for at least 48h prior
to APD. Seventeen patients remained hyper-
calcaemic (median 3.0mmol - 1) and received APD
as a 2h infusion in 500ml of 0.9% saline at a
dose of 15mg if calcium >2.9mmoll-1, or 5mg
if <2.9mmol1-1. Intravenous saline was continued
and further APD given only if no response was
seen at 48h. Thirteen of 17 patients achieved
normocalcaemia with serum calcium falling steadily
over 4 days (median 2.5mmol1-1) with a
concomitant fall in urinary calcium excretion. Ten
patients responded to a single dose of 15mg, one
to 5mg, one to 5mg+O0mg and one to
15mg+ 15mg. One patient died within 24h of APD
due to overwhelming disease and septicaemia.
Three patients failed to respond after total doses of
80, 90 and 120mg of APD. Observation of patients
who did not require additional systemic therapy
revealed rebound hypercalcaemia after 10-14 days.
This study shows that a single administration of
15mg APD is sufficient to control hypercalcaemia
in the majority of patients with hypercalcaemia
secondary to metastatic breast cancer.204 ACP 1st ANNUAL MEETING
Improved treatment of inoperable epithelial ovarian
cancer - results of a combined modality programme
F.G. Lawton, N. Stuart, J.J. Mould,
A.D. Chetiyawardana, K.K. Chan, T. Latief,
D. Spooner & G. Blackledge
For the West Midlands Ovarian Cancer Group
(WMOCG). Departments ofGynaecology,
Radiotherapy and Medicine, Queen Elizabeth
Medical Centre, Birmingham, UK.
Patients with inoperable epithelial ovarian cancer
(EOC) have an inferior prognosis compared with
those whose disease is optimally debulked at primary
surgery. Recent WMOCG trials have shown that
chemotherapy (CT) can render inoperable disease
operable, but that secondary surgery carried out
6+ months after primary laparotomy was not
associated with improved survival. Early second
surgery (Intervention Debulking Surgery - IDS)
carried out as soon as CT has produced sufficient
cytoreduction to make this feasible may be a more
logical approach since the emergence of a clone of
tumour cells resistant to further CT may not have
occurred. Thirty-seven patients with residual
ovarian cancer following primary surgery received
three courses cis-platinum 75mgm 2, adriamycin
50mgm-2 and bleomycin 15mgm-2 (PAB), given
by intravenous infusion with hydration every three
weeks. This was followed by six courses of
escalating cyclophosphamide (1 gm-2 in 0.5gm-2
increments) (esc-C) given three-weekly. IDS was
carried out in suitable patients as soon as the
surgeon felt that further surgery was possible.
Thirty-six patients are currently evaluable for
response and toxicity. Sixteen patients were not
considered for IDS. Twelve patients had <2cm
peritoneal seedlings only following primary surgery,
and 4 patients had macroscopic disease (3 intra-
hepatic, 1 para-aortic nodes), which was felt to be
unresectable. These received the chemotherapy
programme only. Twenty patients who had
undergone 'biopsy only' at primary laparotomy
were considered for IDS after the second or third
course of PAB if the referring gynaecologist felt
that sufficient cytoreduction had occurred to make
surgery feasible. Thirteen had 'good' surgical results
at IDS, 10 no macroscopic disease, and 3 <2cm
macroscopic disease following IDS. One patient
had inoperable disease, and IDS was not performed
in 6 patients because of progression (3), or medical
condition precluding surgery (3). Overall 25/36
(70%) patients (12 at primary laparotomy, 13
following IDS) had disease <2cm or no
macroscopic disease within 12-14 weeks of
diagnosis, at a time when further effective CT could
then be given. Toxicity was tolerable and
predictable. Five patients experienced WHO grade
3 nausea and vomiting. Alopecia was reversible in
all cases. WHO grade 3 myelosuppression occurred
on 8 occasions in 6 patients. Ten patients had
infective episodes which responded to antibiotics.
Six patients had greater than 30% reduction in
creatinine clearance. One patient had a pulmonary
embolus following IDS. There were no treatment
related deaths. Although follow up is short, no
patient has so far progressed in the IDS group, and
the encouraging initial results have led us to initiate
a randomised trial to test this treatment
programme.
The prognosis of untreated stage I ovarian epithelial
cancer
C.J. Gallagher, M. Burnell, E. Wiltshaw
& J. Staffurth
Gynaecological Unit, Royal Marsden Hospital,
Fulham Road, London SW3 6JJ, UK.
The value of adjuvant therapy for stage I ovarian
epithelial carcinoma following optimal surgery and
clinical investigation is unproven. A policy of no
post-surgical therapy for all stage I epithelial car-
cinomas was adopted in this department in 1979. The
aim was to follow newly diagnosed FIGO stage I
patients with laparoscopies every 6 months for 2
years; to determine their survival, rate of relapse,
salvage rate and the morbidity/mortality of repeated
laparoscopies. This group comprises 33 patients
with stage Ia-Ic, in whom surgical staging included
a TAH and BSO in 32 with a negative post-
operative ultrasound or lymphangiogram in 29.
Borderline tumours were excluded. Only 7 patients
had well differentiated stage Iai disease. A median
of 3 laparoscopies per patient were performed.
Bowel perforation requiring laparotomy occurred in
one. Seven have relapsed with a median follow-up
of 39 months. Five out of the 7b relapses were
detected by laparoscopy. The other 2 patients
relapsed at 30 and 41 months. Relapse was not
related to substage, histology or tumour differen-
tiation. Six patients were treated at relapse with
single agentchemotherapy -cis-platinum 100mgm-2
orcarboplatin 400mgm 2. Acomplete remission was
achieved in 3 patients who remain disease free for
12 to 41 months. Two patients have died from their
disease. This represents a 2 year survival of 94%
and disease free survival of 79%. Post-operative
adjuvant treatment has been avoided in these
patients with stage I ovarian cancer. Early detection
of relapse at laparoscopy has enabled the successful
salvage of 3/6 patients with chemotherapy.ACP 1st ANNUAL MEETING 205
Chemotherapy with cis-platinum, vincristine,
methotrexate and bleomycin (POMB) for advanced
carcinoma of the cervix
G.J.S. Rustin" 2, E.S. Newlands2 & Barbara
Southcott2
2Departments ofMedical Oncology and
Radiotherapy, Charing Cross Hospital, London and
'Regional Radiotherapy Centre, Mount Vernon
Hospital, Northwood, Middlesex, UK.
Because ofthe poor results of surgery+radiotherapy
in patients with squamous cell carcinoma of the
cervix who have lymph node involvement or recur-
rent disease the additional use of chemotherapy has
been investigated. Twenty-three patients were
treated up to October, 1985, of whom 14 had
received prior radiotherapy (recurrent). They
received 2-6 courses of vincristine 1.0mgm-2 and
methotrexate 300mgm-2 as 12h infusion on day 1,
followed by folinic acid rescue, bleomycin 30mg
as 48 h infusion days 2, 3 and cis-platinum
100mgm-2 as 12h infusion on day 4. One, who
had WHO performance of 3, died one month after
the start of reduced dose chemotherapy and is not
assessable for response. Of the remaining 22
patients, 6 had a complete remission (IB, IIIB,
2 IVs and 2 recurrent IIIBs), 11 had a partial
remission (1B, IV and recurrent IIB, IIIB and 7
IVs) and in 5 patients there was no change (2 IVs
and recurrent IIIB and 2 IVs) for an overall
objective response rate of 77%. Although 14
patients have since died of their disease, 3 patients
with recurrent or stage IV disease are alive with no
evidence of diease 3+ years off treatment. This has
prompted us to further study the role of multiple
modality therapy using chemotherapy as the initial
treatment in patients with visceral or nodal
involvement from carcinoma of the cervix.
Improved response and survival using ifosfamide in
the treatment of metastatic soft tissue sarcoma
W.P. Steward', D.P. Deakin2, R. Swindell3,
D. Crowther' & M. Harris4
'CRC Department ofMedical Oncology,
Departments of2Radiotherapy, 3Medical Statistics
and 4Histopathology, Christie Hospital & Holt
Radium Institute, Manchester M20 9BX, UK.
Over a 9 year period 55 patients (pts) with metas-
tatic soft tissue sarcomas (STS) have been treated
with a 4-weekly cyclophosphamide, adriamycin,
vincristine and DTIC (CYVADIC) and 47 pts have
been managed with single agent ifosfamide or with
combinations ofchemotherapy containing ifosfamide
(Ifos).
Subjective toxicity for all Ifos combinations was
significantly less than for CYVADIC and the
duration of inpatients' stay was also reduced.
The response rate to CYVADIC was 37% and to
Ifos-containing regimens was 50%. The median
survival from starting CYVADIC was 7 months
and from commencing Ifos was 12 months
(P=0.04). The median relapse-free survival for
CYVADIC was 8 months and for Ifos was 12
months (P=0.2).
Ifos is an important agent in the management of
metastatic STS and should be considered for
inclusion in all combination regimens.
The HTLV-ITI receptor, mechanisms of infectivity,
and possible modes of treatment
A.G. Dalgleish', R.A. Weiss', P. Clapham',
M. Marsh', P.J. Maddon2, R. Axel2
'Institute ofCancer Research, Royal Cancer
Hospital, Chester Beatty Laboratories, Fulham
Road, London SW3 6JB, UK and 2Columbia College
ofPhysicians and Surgeons, NYC, USA.
Previous studies by our group have shown that the
T4 antigen of the helper-inducer subset of cells is
an essential component of the HTLV-TII receptor
(Nature, 312, 763, 1984). Using cell lines transfected
with the human T4 genome (Cell, 40, 237, 1985),
we have been able to show that mice fibroblasts
and lymphocytes expressing the human T4 antigen
are resistant to infection with HTLV-I11. We have
since obtained a variety of human cells which do
not normally express T4 but which, following
transfection with the T4 genome, now do so,
Preliminary data suggest that T4 binds to the
envelope gene of HTLV-IT1 and that a further
component not expressed on mouse cells may be
required for infection.
The virus probably follows the endocytic
pathway described for other retroviruses and
studies using endocytic inhibitors that support these
data will be presented. These agents are in distinct
contrast to those that inhibit the reverse
transcriptase of the virus and have been tested in
vitro (and one in vivo) by our laboratory. Studies
on how the virus evades effective immunologic
responses previously reported (Nature, 316, 69,
1985) will be updated with particular reference to
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The mechanism(s) whereby the virus causes
6cancer' in 40% of AIDS patients will be discussed
with special emphasis on the importance of the
above studies to the development of Kaposi's
sarcoma.
Detection of malignant lymphoma in the liver:
Correlation between magnetic resonance imaging at
0.08 Tesla and open liver biopsy
M.A. Richards', J.A.W. Webb2, R.H. Rezneck2,
S.E. Jewell2, T.A. Lister' & P.F.M. Wrigley'
1ICRF Department ofMedical Oncology and
2Department ofRadiology, St Bartholomew's
Hospital, London ECIA, UK.
The assessment of liver involvement in patients
(pts) with malignant lymphoma by clinical
examination, conventional imaging techniques and
biochemical tests of liver function is notoriously
inaccurate. High false negative rates with
percutaneous liver biopsy have been demonstrated.
An accurate non-invasive method of detection of
hepatic lymphoma would be of considerable
benefit.
This study correlates the results of spin lattice
relaxation time (Ti) measurements made by
magnetic resonance imaging (MRI) at 0.08 Tesla
with the pathological findings from liver biopsy
in pts undergoing laparotomy for malignant
lymphoma.
Seventeen pts- 13 with Hodgkin's disease (HD)
and 4 with non-Hodgkin's lymphoma (NHL) - and
24 healthy volunteers have been scanned to date.
Six of the 17 pts had histologically confirmed
hepatic lymphoma (2 HD, 4 NHL). All 6 had
diffuse elevation of liver TI (>3 standard
deviations above the mean for healthy volunteers:
P<0.0001). One of these pts had additional focal
liver abnormalities.
Eleven pts had no evidence of lymphoma on
wedge liver biopsy. Nine of these had liver TI
measurements within the normal range. The tenth
pt had slight elevation of liver TI and liver
histology was compatible with chronic active
hepatitis. The final pt had a normal liver biopsy,
but marked elevation of liver TI, the significance of
which is unknown.
These early results suggest that MRI at low field
strength may be helpful in the detection of hepatic
involvement by lymphoma.
Intensive 6 week remission induction followed by
3-weekly consolidation therapy for high grade
non-Hodgkin's lymphoma
N.S. Stuart, G.R.P. Blackledge, J.A. Child,
A. Simmons, S. Cartwright, D. Barnard, M. Cullen
& J. Fletcher
West Midlands and Yorkshire Lymphoma Group
In an attempt to improve complete remission rate
and overall survival we have used an intensive, 6-
week, 4-drug remission induction regime (VAMP:
vincristine 2mg i.v. wks 1-6, adriamycin 50mgm-2
i,v. wks 1, 3, 5, methotrexate 250 mgm-2, i.V.
wks 1, 3, 5 with folinic acid orally for 3 days,
prednisolone 60mg/day wks 1-6 reducing over
10 days) followed by a 3-weekly non-cross resistant
consolidation regime (CViVp: cyclophosphamide
Igm-2, vindesine 3mgm-2, etoposide 125mgm-2
all i.v. day 1, etoposide 250mgm-2 days 2, 3 - all
repeatedday21). Patients received at least 3 courses of
CViVp following CR. One hundred and twenty
patients with high-grade (Kiel) non-Hodgkin's
lymphoma have been treated with this regime. Mean
follow-up is 21 months, all patients have completed
treatment. Mean age ofthe group was 54 years (range
14-78).Twenty-fivepatientswerestage(S)1/IIallwith
bulky, symptomatic or abdominal disease, 89 were S
III or S IV. Sixty-five had B symptoms.
At the end of VAMP 53 patients (46%) were in
CR. Of the 50 in PR at the end of VAMP 20
achieved CR during CViVp. Overall best status
achieved was CR 75 (65%), PR 33 (29%), fail 9
(7%). Median survival of responders and median
relapse free survival have not yet been reached. The
proportion of patients receiving greater than 75%
of protocol doses for each drug was as follows; adr,
73%; vincr, 61%; meth, 64%; pred, 92%; vind,
70%; cyclo, 77%; VP-16, 73%. Toxicity was
acceptable in both phases of treatment. No
neutropaenia below 0.5 x 1091-1 was recorded in
58% of patients during VAMP; 72% during
CViVp. No platelet count below 50x 10121-1 was
recorded in 93% during VAMP; 95% during
CViVp. Moderate or severe neuropathy occured in
25% of patients during VAMP. Septicaemic
episodes occurred in 24/122 (19%) patients.
Fourteen deaths occurred to which treatment
contributed, in 8 of these other causes were also
involved.
This regime appears effective and well tolerated.
Results are as good as those achieved with any
other regime particularly with regard to the large
proportion of elderly patients and those with
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Etoposide containing combination chemotherapy
(CT) for Hodgkin's disease (HD)
T.J. Perren, P.J. Selby, E.K. Mbidde
& T.J. McElwain
Section ofMedicine, Institute ofCancer Research,
Royal Marsden Hospital, Surrey, UK.
Thirty-nine patients (pts) (20 clinical stage (CS) IV,
9 CS III, 10 CS II - poor prognostic factors) were
treated with OPEC (vincristine 1.4mgm-2 day (D)
1 and 8, prednisolone 40mg/day D 1-14, etoposide
200mgm-2 orally (p.o.) daily D 1-5, chlorambucil
6mgm-2 p.o. daily D 1-14). In 30 (28 previously
untreated pts and 2 relapsing 9 years after previous
treatment) this was alternated with ChIVPP (an
established CT regimen - O/C) while 9 pts relapsing
after previous treatment received OPEC alone (0).
Median follow up is 40 months; complete remission
(CR) rate 20/28 (71%) of O/C pts and 5/9 0 pts;
median relapse free survival has not been reached
for O/C and was 44 months for 0; actuarial 3 year
survival was 77% for O/C and 60% for 0.
Twenty-nine patients relapsing from previous CT
have been treated with HOPE-Bleo (adriamycin
40mgm-2, vincristine 1.4mgm-2 day 1 and 8,
prednisolone 40mgm-2 daily D 1-8, etoposide
200 mgm-2 p.o. daily D 1-4, bleomycin lOmgm-2
day 1 and 8). Median follow up 12 months; CR
14/29 (48%); median relapse free survival 11
months and 2 year actuarial survival was 54%.
Nausea and vomiting, alopecia and myelo-
suppression sufficient to delay treatment were seen
in 49%, 100% and 18% of OPEC pts and 55%,
100% and 21% of HOPE-Bleo pts respectively.
Etoposide can be combined safely and effectively
with other agents in both first line and relapse
regimens in HD.
Studies of high dose chemotherapy in multiple
myeloma (MM)
T.J. Perren1, P.J. Selby', R.K. Mbiddel,
J.S. Malpas2 & T.J. McElwain'
'Department ofMedicine, Institute ofCancer
Research and Royal Marsden Hospital, Downs Road,
Sutton, Surrey and 2Department ofMedical
Oncology, St Bartholomew's Hospital, London ECJ,
UK.
Forty-one previously untreated patients (pts) aged
<63 years with MM were treated with HDM
14Omgm-2 i.v. Median follow up is 16 months
(R 4-47). Eleven (27%) achieved complete remis-
sion (CR - normal bone marrow morphology and
unmeasurable paraprotein), and 21 (51%) partial
remission (PR - >50% reduction in paraprotein
and improvement in all other clinical features). CRs
seem durable with no relapses to date whereas
10/21 PR patients have relapsed (P<0.05). All
patients had nausea, vomiting, diarrhoea and
mucositis as well as WHO grade 4 myelo-
suppression. Median recovery of leucocytes
(>1 x 109 1-1) and platelets (>25 x 109l-1)
occurred at 28 and 24 days respectively. There were
8 treatment related deaths, usually from sepsis
and/or bleeding. In a group of 15 heavily pretreated
pts, the response rate was also high (66%) but there
have been no durable remissions. In relapsed
heavily pretreated pts we have used high dose
methylprednisolone (HDMP -1 gm-2/i.v. daily x 5
repeated q. 21 days). Of 9 patients evaluable for
response there were 4 PRs of short duration (2-6
months) with minimal toxicity. Our present study
combines HDM with a single 5 day course of
HDMP. Median follow up is 4 months; 9/12 pts
are evaluable for response, 4 achieved CR and 5
PR. Overall there was no increased toxicity and in
particular no treatment related deaths.
HDM with or without HDMP seems a promising
treatment for young previously untreated pts with
MM and may be superior to standard therapy.
Measurement of psychological morbidity in patients
with advanced cancer of the breast
P. Hopwood & A. Howell
Department ofPsychiatry, University Hospital of
South Manchester and CRC Department ofMedical
Oncology, Christie Hospital, Manchester, UK.
The aim of the study was the evaluation of 2
screening instruments in the detection of
psychological morbidity in patients with advanced
breast cancer. The self-rating scales used were the
Hospital Anxiety and Depression Scale (HADS.
Zigmond & Snaith, Acta Psychr. Scand., 67, 361,
1983) and the Rotterdam Symptom Checklist
(RCL. de Haes et al., Ned Tijd. Phsychol., 38, 403,
1983).
Two hundred and ten out of two hundred and
thirty-five patients completed both questionnaires
on one or more occasions, an overall compliance of
89%. Both instruments identified 31-34% patients
with high scores on at least one occasion, and a
similar proportion of patients with borderline
scores.
Eight-one patients were also assessed using a
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Interview Schedule (CIS, Goldberg et al., Br. J.
Soc. Prev. Med., 24, 18, 1970) to assess the validity
of the two instruments. Twenty patients received a
psychiatric diagnosis (depression or anxiety), 11
were borderline cases and 50 were psychologically
well. The sensitivity of the RCL in identifying cases
of morbidity was 75% with 80% specificity. For
the HADS the sensitivity was 75% for depression
and anxiety and the specificities 75% and 90%
respectively. Both instruments performed less well
in identifying borderline cases (60-73%).
We conclude that both instruments are equally
accurate in detecting cases of psychological
morbidity but identify slightly different patient
groups. The HADS has a potential advantage in
being able to discriminate cases of depression and
anxiety. Both instruments require further refine-
ment to be of use in detecting borderline cases.
Quality of life after treatment for testicular cancer
N.S.A. Stuart, R. Grundy, C. Woodroffe
& M.H. Cullen
Queen Elizabeth Hospital, Edgbaston, Birmingham,
B15 2TH, UK.
Recent advances in chemotherapy have led to the
prospect of cure for the majority of patients with
non-seminomatous germ cell tumours. The
immediate subjective toxicity of such chemotherapy
is well known, but the long-term effects on quality
of life have not been reported. By means of a
category-rating type questionnaire we have assessed
the effects of treatment for testicular cancer on 2
groups of patients. The study group comprised 36
patients (28 replies) who had received chemo-
therapy, the control group comprised 54 patients
(34 replies) matched for age, social group and time
since start of treatment, who had been treated with
radiotherapy. Median time since start of treatment
was 32 months in each group.
Results showed there to be no difference between
the 2 groups in their assessment of their general
health and fitness or in their job prospects since
treatment. The majority of patients in both groups
felt as fit and as healthy as before their illness and
remained in full-time employment. There was no
difference in the groups' assessment of changes in
the quality of their relationships with wife, friends
or family. Both groups reported an improvement in
such relationships since treatment. Both groups
reported that they worried more about the future in
general and about their health since treatment, and
felt they were more often depressed - all but the
former being more marked in the control group.
Hearing difficulties since treatment were more
frequent in the study group (39%; controls=12%;
P=0.05) and 3 study patients reported Raynaud's
phenomenon (controls =0). At least 39% of the
study group were still fertile, 7 having fathered
children.
We are encouraged that current chemotherapy
does not substantially increase the long-term
emotional, psychological and social effects of
diagnosis and treatment for testicular cancer.
However, there is scope for reducing the physical
side-effects of treatment.
Psychiatric morbidity following mastecomy, the value
of counselling
P. Whitford, J.M. McArdle & C.S. McArdle
University Department ofSurgery, Royal Infirmary,
Glasgow, UK.
Anxiety and depression are common following
mastectomy. The incidence is higher in patients
with a past history of depression, severe marital
problems, social problems or who lack a close
confidante. In this study two groups of patients,
one of which received informal counselling from a
Nursing Sister following mastectomy, were studied.
Psychiatric morbidity was measured by means of
self administered questionnaires, the general health
questionnaire (GHQ) and the Leeds Scales of
depression (LSD) and anxiety (LSA). Twelve
months after mastectomy, psychiatric morbidity
was present in 46% of control patients, depression
in 40% and anxiety in 54% (Table). The incidence
of depression and anxiety in patients receiving
informal counselling was significantly lower. The
incidence of risk factors was similar in both groups.







These findings suggest that the high incidence of
anxiety and depression following mastectomy can
be reduced by informal counselling.ACP 1st ANNUAL MEETING 209
Transcatheter embolisation to control severe bleeding
.in breast cancer
E.M. Rankin', R.D. Rubens' & J.F. Reidy2
'Department ofClinical Oncology and 2Department
ofRadiology, Guy's Hospital, SE] 9RT, UK.
Haemorrhage from fungating breast cancer is
uncommon but alarming. Recourse to ligation of
the internal mammary artery when simple measures
fail (e.g. pressure bandages, suture of bleeding
point) may be inappropriate in frail patients with
advanced disease.
Transcatheter embolisation of the arteries
supplying the tumour offers an alternative approach
to the problem. The internal mammary artery is
approached via the ipsilateral femoral artery using
interventional radiology techniques and the tumour
blood supply is demonstrated. Various agents
including gelfoam, steel coils, Ivalon, alcohol and
dextrose may be injected to produce occlusion and
sclerosis. Since only a local anaesthetic with
systemic sedation and analgesia are needed the
problem of general anaesthesia is avoided.
Eight patients (ages 44-74 have been treated; in
7 immediate control of bleeding was secured, and in
6 no further haemorrhage occurred (longest follow
up to date 22 weeks). In 1 patient another
haemorrhage 2 months later was stopped by
embolisation of the newly developed collateral
circulation to the tumour. The tortuous vascular
anatomy in 1 patient prevented entry into the
internal mammary artery and so embolisation was
not possible. The only side effect of the procedure
has been some pain following injection of
sclerosant. Subsequent response to chemotherapy is
not affected by embolisation. This is a safe
procedure and prophylactic embolisation should be
considered in patients at risk.
Single high dose aminohydroxypropylidene
diphosphonate (APD) infusions to treat
cancer-associated hypercalcaemia
B.M.J. Cantwell & A.L. Harris
University Department ofClinical Oncology,
Regional Radiotheapy Centre, Newcastle General
Hospital, Newcastle upon Tyne, UK.
Ralston et al. (Lancet, ii, 907-910, 1985) reported
intravenous (i.v.) daily infusions of APD to treat
cancer-associated hypercalcaemia, and serum
calcium levels fell significantly by day 2. Side effects
of daily i.v. infusions of APD include transient
fevers and drip site thrombophlebitis.
We have treated more than 15 patients with
cancer-associated hypercalcaemia. Analysis of first
10 patients treated is as follows: mean age 54.2
years, range 41-76, comprising 3 women with
breast cancer and 7 men. APD 30mgs in 500mls of
0.9% saline was infused i.v. over 2h. Normo-
calcaemia (serum calcium 2.25-2.75mmoll-1) was
achieved with APD in all but 2 patients who,
despite substantial reductions in serum calcium
levels did not achieve normocalcaemia. Mean
(SEM) for pre-APD and post-APD serum calcium
levels were 3.16 (0.11) and 2.56 (0.10)mmoll-P
respectively, and for maximum pre-APD and
minimum post-APD levels 3.29 (0.12) and 2.38
(0.10)mmoll-1 respectively. Significant fall in
serum calcium levels occurred with APD
P= <0.005 for both pair groups (Wilcoxon tests, 2-
tailed probabilities). Time to normal or minimum
serum calcium was 1-8 days from start of APD
therapy, and in those patients achieving normo-
calcaemia serum calcium remained normal for >5
weeks in 3 patients. There were no side effects with
APD except for mild transient fever within 1 day of
administration in 3 patients. Single i.v. infusions of
30mg APD every 2-3 weeks may be adequate to
treat mild to moderate cancer-associated hyper-
calcaemia. This would be more convenient for
patients than daily treatments and would lessen the
risk of drip site thrombophlebitis.
Weekly oral idarubicin in advanced breast cancer
D.B. Smith1, A. Howell' & G. Thomas2
'CRC Department ofMedical Oncology, Christie
Hospital, Manchester and 2Farmitalia Ltd, UK.
Idarubicin is an anthracycline analogue with
approximately 30% bio-availability when adminis-
tered orally. The major metabolite of Idarubicin,
13-OH 4DMDNR, is of equal anti-tumour activity
to the parent compound in animal systems and
since it is still present in the serum 7 days after
dosing it was thought that a weekly schedule might
be of benefit by mimicking a continuous infusion
of cytotoxic activity. Thirty-eight patients with
advanced breast cancer who had not received
prior chemotherapy were treated with Idarubicin
15mgm-2wk-1. Median age was 61 (33-79) and
dominant sites of disease were: Stage IV primary 9,
bone 9, lung 6, cutaneous 6, lymph nodes 3 and
retroperitoneal infiltration 2. Fourteen patients had210 ACP 1st ANNUAL MEETING
previously responded to hormone therapy while 18
had shown no response and 6 had had no hormone
treatment. The major toxicity was nausea+vomiting
affecting 32% of courses, 4 patients (10.5%)
requiring dose reduction for intractable symptoms.
Three patients noted partial alopecia and there
were no episodes of cardiac failure. Neutropenia
(bc 2.5<1091-1) resulted in 9 dose reductions and
9 treatment delays. There was no platelet toxicity
and no episodes of infection. With a median
follow-up of 28 weeks (8-60) there has been 1 CR
(duration 11 + months) and 5 PRs (duration 11 +,
7+, 6+, 3+ and 3+ months), an overall response
rate of 15%. However, a further 6 patients had
no change for 6+ months and thus 30% either
responded or had static disease. Oral Idarubicin in
a weekly schedule is comparatively non-toxic and
has moderate activity in advanced breast cancer
but does not appear to be superior to a q. 21 day
regimen.
Phase II trial of mytomycin C (MC) and
5-fluorouracil (5-FU) in advanced previously treated
breast cancer
E.J. Bayliss, M.E. Kerr, J.F. Smyth
& R.C.F. Leonard
University Department ofClinical Oncology,
Western General Hospital, Edinburgh, UK.
Patients (pts) with advanced breast cancer and who
relapsed after or became resistant to adriamycin
regimes have been treated with MC/5-FU (MC,
6mgm-2 max 10mg q. 6/52 and 5-FU 1 gmm-2 q.
3/52). Twenty of 25 pts have received minimum one
full course, 19 evaluable for response. Five patients
received course IA only at half dose and died of
disease (4 pts) or GI haemorrhage (1 pt at day 5).
Fourteen of 19 pts had visceral (10 pts) and/or
multiple sites involved. Patients received 1-5 cycles
(median 2) producing 6/19 PR and 13/19 NR. The
median duration of response is 84 days (34-158
days) and survival median 131 days (74-486 days).
Both responders and non-responders had similar
extent of prior treatment (PR median 8, range 6-12
cycles; NR median 6, range 3-21 cycles). Toxicity
was acceptable for the 19 evaluable pts; nausea and
vomiting, grades 0/I 68%, II/III 32%; neutropenia
grades 0/I 42%, II/III 52%, IV 6%; thrombocyto-
penia 0/I 81% 11/III 19%. Alopecia and clinical
pulmonary deterioration did not occur. In summary
*MC/5-FU is active (OR 32%) and has acceptable
toxicity for patients who have been previously
treated for advanced breast cancer.
The effect of aminoglutethimide (AMG) on liver
function tests (LFTs) in advanced breast cancer
E.J. Bayliss', P. Levack2, U. Chetty2
& R.C.F. Leonard1
Department of IClinical Oncology and 2Clinical
Surgery, Western General Hospital, Edinburgh, UK.
Abnormal LFTs occur in patients (pts) on AMG,
being attributed variously to hypersensitivity,
induction of liver enzymes, hepatic toxicity or
unmasking of hepatic metastases (mets). We have
reviewed our experience of AMG in breast cancer
and 24 pts with no clinical and/or ultrasonic
evidence of liver mets were considered evaluable
with normal (<40ul-1) alanine amino transferase
(ALT) and normal gamma glutamyl transpeptidase
(GGT, <35 u -1) pre-treatment. All had either
serial LFTs performed during the first 6 months of
AMG or at least one measurement during AMG
and 1 or more measurements after cessation of
AMG. Three pts with known liver mets and normal
LFTs were also studied. In all 24 pts GGT rose by
minimum 75% on AMG from mean 18.5ul 1-
(range 5-35) pre-treatment to highest measured of
mean 128ul-1 (range 23-471). Corresponding
values for ALT were 20.7uP1 (10-37) at start and
51.3ul-1 (11-202) maximum (>50% rise in 13).
For alkaline phosphatase the initial mean was
94u1-1 (43-205) and maximum 130.6u1-1 (41-
1033) respectively and those with no bony mets
82ul1- (43-205) at start and 106 (41-286)
maximum (>25% rise in 6, > 10% rise in 14
patients). In 5 pts GGT was measured as rising at 2
weeks after start of treatment, 11 pts had sufficient
data to show peak abnormalities between 1-3
months for all enzymes and thereafter either falling
rapidly, especially when AMG stopped, or
remaining abnormal up to 12 months in some of
the pts who continued AMG. The 3 pts with
known liver mets and normal LFTs showed similar
patterns before developing clinically progressive
disease in liver and symptoms thereof. The
transience of elevation suggests enzyme induction
rather than direct hepatotoxicity. The phenomenon
can be misconstrued as progressive liver disease in
this group of 'at risk' patients.ACP 1st ANNUAL MEETING 211
Beneficial effect of high dose tamoxifen in patients
with advanced breast cancer not responding to
standard doses
Sylvia M. Watkins
Department ofMedical Oncology, Lister Hospital,
Stevenage, UK.
The effect of increasing the dose of tamoxifen from
20-40mg to 90mg daily was studied in 25 post
menopausal breast cancer patients (aged 46-83),
whose disease was progressing on the lower
('standard') doses. On standard doses of tamoxifen
there had been 3 complete, 3 partial remissions
(PR), 9 with stable disease (SD) all followed by
progressive disease (PD); the remaining 10
progressed relentlessely (UICC criteria). On the
high dose there was 1 PR lasting 5 months and 16
SD lasting 3 to 19 months (median 6 months). Side
effects were slight (lethargy, tiredness, loss of taste
and hot flushes in 4 patients). There was no
correlation between response to standard dose and
high dose tamoxifen, and no correlation between
response and plasma levels of tamoxifen.
In spite of the low objective response rate on the
higher dose, two-thirds of the patients had a period
of stable disease lasting sometimes many months,
and in view of the minimal side effects this was a
worthwhile outcome of treatment in this group of
patients. Comparable results were found by Stewart
et al. (Cancer Treatment Rep., 66, 1445, 1982).
Increasing the dose of tamoxifen is a useful and
acceptable approach in cases of primary and
secondary failure of tamoxifen treatment, and well
worth trying before switching to other forms of
endocrine therapy or chemotherapy, all of which
have more serious side-effects.
Very high dose cyclophosphamide (HDCY) followed
by cis-platinum (CP) in advanced ovarian cancer
R.J. Osborne', B.D. Evans2, C.D. Wood1,
C.J. Gallagher2, M.L. Slevint, J.H. Shepherd3
& E. Wiltshaw2
Departments of'Medical Oncology and
3Gynaecological Oncology, St Bartholomew's and
Hackney Hospitals and 2Department ofMedicine,
Royal Marsden Hospital, London, UK.
Twenty patients (pts) with previously untreated
ovarian cancer (12 stage III, 8 stage IV) received
intensive chemotherapy after initial surgery (small
residual 11, bulk residual 9). Treatment Plan HDCy
7gm-2 with mesna 10.5gm-2 for 2 courses,
followed by re-evaluation with second look
laparotomy followed l6y CP 1OOmgm-2 for 5
courses. Two initiat pts received 3 cycles of HDCy,
15 pts received 2 cycles of HDCy, 3 pts received 1
cycle HDCy. Fifteen of 20 pts subsequently
received CP (mean 4 courses). Results HDCy
Pathologically documented complete remission
(PDCR) - 3/14 pts (21%). Partial remission (PR)
8/14 (58%). Progression 3/14 (21%). Unassessable -
(no second look laparotomy) 6 pts. Toxicity There
was evidence ofcumulative marrow toxicity.
Days neutrophils Days platelets
Course I x 1091-1 mean 1 x 1091-1 mean
HDCy Pts (range) (range)
1 20 12.2 (8-16) 8.0 (0-13)
2 15 19.6 (8-115) 25.8 (3-116)
3 2 20 (14-26) 59.5 (19-100)
Two pts died from treatment related causes (1
septicaemia, 1 persistent bone marrow hypoplasia).
Overall Results After HDCy and CP (20 pts).
PDCR 4 pts. Clinical CR 4 pts. Alive in relapse 4
pts. Died 7 pts. Survival Median survival of whole
group 20 months. Conclusion HDCy is toxic
therapy, and the pathologically documented
complete remission rate is not greater than that
expected with conventional therapy.
A pilot study of carboplatin (JM8) and chlorambucil
(CLB) in epithelial ovarian carcinoma
S.B. Kaye, M. Harding, S.J. Harland, J. Graham,
Lesley Mill, A. McLean, R. Kennedy, I. Duncan,
J. Kennedy & M. Soukop
Departments ofMedical Oncology and Gynaecology,
University ofGlasgow, Glasgow Royal Infimary and
Ninewells Hospital, Dundee, UK.
To date, 32 patients with previously untreated
ovarian carcinoma (FIGO Stages II, III or IV) have
received JM8 300mgm-2 and chlorambucil 10mg
daily for 7, 10 or 14 days to assess the toxicity of
this combination prior to a randomised Phase III
trial comparing the efficacy against that of single
agent JM8. The major toxicity was myelo-
suppression and chemotherapy was delayed beyond
the planned 4 weekly interval by WHO Grade I
leukopenia. Subsequent courses were given with




+ No. of Total No. (dose
CLB patients treatment cycles reduced) WBC Plats
7 days 16 9 49 6 (7) 3.2 131
10 days 5 1 29 16 (12) 3.1 135
14 days 11 7 36 13 (16) 3.1 154212 ACP 1st ANNUAL MEETING
Treatment was well tolerated on an outpatient
basis in most cases with WHO Grade 0-2 nausea
and vomiting, a single patient experienced moderate
alopecia. A clinical response has been documented
in 10 of 16 evaluable patients. The study is ongoing
to confirm that the combination of JM8
300mgm-2 with chlorambucil 10mg daily for 7
days is as feasible as these preliminary data suggest.
A randomised comparison of three platinum
analogues in combination with cyclophosphamide in
patients with advanced epithelial ovarian cancer
H. Anderson1, J. Wagstaffl, D. Crowther'
& M. Timms2
1CRC Department ofMedical Oncology, Christie
Hospital, Manchester, M20 9BX and 2ENT
Department, Manchester Royal Infirmary, Oxford
Road, Manchester 13, UK.
Twenty patients have now been entered into each
of the three arms of a pilot study comparing cis-
platinum 100mgm-2 with CHIP 240mgm-2 and
CBDCA 300mgm-2 in combination with cyclo-
phosphamide 600mgm 2. Cycles of therapy are
repeated at four weekly intervals for a total of six
courses. This abstract (Nov., 1985), is of data from
42 patients who have completed therapy, and the
data will be updated by March, when almost 60
patients will have completed therapy.
Cis-plat CBDCA CHIP
Total number ofpatients 14 11 17
No. patients
dose reduction/delay 6 6 15
Response
CR/PR 11 7 11
Stable 0 2 0
Progression 1 0 5
Not evaluable 2 2 1
Toxicity
Nausea & vomiting 14 (3)a 11 (2) 17 (2)
Alopecia 14 (3) 10 (2) 15 (2)
Diarrhoea 2 1 13 (2)
Tinnitus 12 5 3
Deafness 6 2 0
Paraesthesiae 9 1 3
aNumber of patients followed by median WHO toxicity
grade in brackets. Haematological toxicity has been seen
in all arms and is most severe in CHIP patients
necessitating frequent dosage reduction in therapy and in
CBDCA patients to a lesser extent. Renal toxicity has only
been seen in cis-platinum treated patients.
Successful management of metastatic and primary
germ cell tumours in the brain
G.J.S. Rustin, E.S. Newlands, K.D. Bagshawe,
R.H.J. Begent & S.M. Crawford
Cancer Research Campaign Laboratories,
Department ofMedical Oncology, Charing Cross
Hospital, London, UK.
Nine men and one woman with brain metastases
from previously untreated non-seminomatous germ
cell tumours have been treated between 1977 and
1984. All the men had lung metastases. Nine
patients had elevated serum values of human
chorionic gonadotrophin (HCG), the level was
greater than 40,000iuI1- in seven. They were
treated with sequential combination chemotherapy,
either POMB/ACE (Newlands et al., Lancet, i, 948,
1983) or EP/OMB (etoposide 200mgm-2, Cis-
platinum 100mgm-2 alternating every 8-10 days
with vincristine 1 mgm-2 methotrexate and
bleomycin 300mg as 48h infusion) but no radio-
therapy. The methotrexate was given at a dose of
1 gm-2 with folinic acid rescue starting at 32h and
intrathecal methotrexate was given during courses
not containing intravenous methotrexate. Eight of
10 patients are alive, off treatment with no evidence
of active disease of whom 5 have been in remission
and off treatment for more than 2 years.
Two patients with primary intracranial non-
seminamatous germ cell tumours were treated in a
similar fashion. One patient died from enlargement
of differentiated teratoma, the other is alive 15 +
months off treatment with no evidence of disease.
These results, which are better than any
previously reported, indicate that chemotherapy is
the preferred treatment of primary or metastatic
non-seminomatous germ cell tumours of the brain
and that only rarely will these patients benefit from
surgery or radiotherapy.
The effect of dose on the bioavailability of oral
etoposide
M.L. Slevin, S.P. Joel, M. Richards, V.J. Harvey,
R. Whomsley & P.F.M. Wrigley
ICRF Department ofMedical Oncology, St
Bartholomew's and Hackney Hospitals, London, UK.
Previous studies from this department have
suggested that the bioavailability of oral etoposide
may decrease as the administered dose increases
(Harvey et al., ASCO, 3, 24, 1984, Cancer
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further investigate this observation and to
determine the dose at which the bioavailability
decreases has been conducted. Ten patients (pts)
with malignant mesothelioma who were receiving
single agent etoposide in a Phase II study have
been investigated. Each pt was studied after oral
etoposide at a total dose of 100, 200, 300, 400 and
600mg. The order of administration of these doses
was randomised. Etoposide was administered at
9am after an overnight fast. Food and drink were
allowed ad libitum 2h after dose. Etoposide
concentrations in plasma and urine were measured
using an HPLC assay (Harvey et al., J. Chrom.,
339, 419, 1985).
Results 100mg 200mg 300mg 400mg 600mg
Mean AUC
(ugml- 1
xhm 2) 38.8 68.9 93.5 105.3 139.5
% increase
over








AUC P=0.3 P=0.06 P<0.0001 P<0.0001
Peak etoposide concentrations and urinary
concentrations followed a similar pattern and did
not achieve the predicted levels. This study
confirms the earlier observation that oral etoposide
bioavailability decreases with increasing dose in
most patients.
Decreased half life of ifosfamide (I) after daily oral
administration
M. Lind1, T. Cerny1, J. Margison2, N. Thatcher'
& P.M. Wilkinson2
1CRC Department ofMedical Oncology and
2Department ofClinical Pharmacology, Christie
Hospital & Holt Radium Institute, Manchester M20
9BX, UK.
Six patients with small cell lung cancer were treated
with (I) 2g p.o. daily for three days. Serial serum
and urine samples were collected over the first 96h
after administration of the first dose and
concentrations of (I) assayed by HPLC using a
method developed in this laboratory. We have
previously showed 100% bioavailability of (I) for
doses up to 2g and that the elimination phase was
identical after equivalent oral or i.v. bolus doses.
Therefore, total clearance, distribution volume and
half-time can all be derived from the oral
concentration/time profile. These values are given
in the table. There was a progressive decrease in
AUC by 40% of the initial value at day 3. This was
associated with a decreased plasma half-time and
increased clearance. The distribution volume
remained unchanged. Similar observations have
been shown for cyclophosphamide and we suggest
that the kinetic changes are due to induction of (I)
metabolism.
Pharmacokinetics of fractionated (I)
Day I Day 2 Day 3
T 1/2h 6.8 5.3 4.8
AUC ,ugl-Ih 608 471 383
CLtotmlmin- 1 54 70 86
VDL1s 32 31 35
An in vitro test for activity of agents potentially
useful in treating human renal cell carcinoma
D. Heinemann1, M.A. Ferro2, A.V. Kaisary3,
P.J.B. Smith2 & M.O. Symes'
Departments of'Surgery and 2Urology, University
ofBristol, Bristol Royal Infirmary, Bristol BS2
8HW and 3Department of Urology, University of
Oxford, UK.
Tumour cell suspensions were prepared from 19
renal cell carcinomas by disaggregation with
collagenase and DNase. Relatively pure suspensions
of carcinoma cells were then separated following
centrifugation of the mixed cell suspension on a
Nycodenz (Nyegaard & Co. As, Oslo) column.
Aliquots of 105 tumour cells were cultured in vitro
with graded concentrations of 5, therapeutic agents
for 24h. Thereafter the cells were washed free of
the agent and resuspended in 2ml of methionine -
free MEM with 24uCi of 75Se (as Seleno-
methionine, SCIP Amersham Int plc) for 48 h.
Incorporated radioactivity in the pellet, as a
measure of protein synthesis, was compared
between cells exposed to a drug and control cells
cultured in medium alone.
Lai et al. (Proc Ist Conference on Neoadjuvant
Chemotherapy, Paris, 1986) using a mouse mammary
carcinoma, showed that >70% inhibition of
75Se uptake predicted a significant anti-tumour
action of the drug in vivo. We found depo-provera,214 ACP 1st ANNUAL MEETING
1.O igml-l produced >70% inhibition of protein
synthesis in 3/19 tumours. The corresponding pro-
portion for vinblastine, 1.0pgml-', was 2/14
and for methotrexate 400Mgml-1, 1/13 tumours.
However, adriamycin, 1.0 ugml-1, was effective
against 4 of 6 tumours and the related drug,
novantrone, against 4 of 8 at 1.0pgml-1 and 6/9
for 10.Ougml-1. The use of novantrone to treat
metastatic renal cell carcinoma might thus be
investigated.
The role of reduced glutathione as a determinant of
cellular sensitivity to 'activated' cyclophosphamide -
A possible role for acrolein
T.R. Crook', R.L. Souhami2 & A.E.M. McLean'
IToxicology Laboratory, University College London,
London WCJ and 2Department ofRadiotherapy and
Oncology, University College Hospital, London
WCJ, UK.
A dual culture system of rat hepatocytes and K562
human leukaemia cell line has been used to
investigate the intracellular metabolism and cell
cytotoxicity of cyclophosphamide (CP). After
exposure to activated CP alkaline elution analysis
of leukaemia cell DNA demonstrated substantial
levels of DNA single-strand breaks, in addition to
DNA interstrand cross-links and DNA-protein cross-
links. Acrolein was shown to be the metabolite
of CP which caused single-strand breaks. Acrolein
was also a highly effective depletor of cellular
reduced glutathione (GSH), but phosphoramide
mustard had no effect on cellular GSH content.
K562 cells depleted of GSH either by Buthionine
sulfoximine (BS) or BCyNU show greatly increased
sensitivity to the cytotoxic and DNA damaging
effects of activated CP, but not to phosphoramide
mustard. Similarly, the cytotoxic and DNA cross-
linking effects of 'activated' CP, but not phos-
phoramide mustard, were antagonised by cysteine.
These results suggest that GSH depletion either by
exposure to agents such as BSO or BCyNU, or
by intracellularly released acrolein itself, increases
the conversion of 4-OH-CP into cytotoxic meta-
bolities. These findings are of importance in
devising novel strategies for overcoming resistance
to CP.
111Indium labelled monoclonal antibody to placental
alkaline phosphatase is of clinical value on the
detection of neoplasms of testis, ovary and cervix
Teresa R.B. Pawlikowska & A.A. Epenetos
On behalfofthe Hammersmith Oncology Group,
Royal Postgraduate Medical School, Hammersmith
Hospital and the Imperial Cancer Research Fund,
London, UK.
Indium-111 labelled monoclonal antibody HI7E2
raised against placental alkaline phosphatase and
testicular placental alkaline phosphatase has
been used to image patients with carcinoma of the
testis, ovary and cervix. Forty-one patients have
been studied with radioimmunoscintigraphy.
Imaging of neoplastic lesions was achieved in the
majority of patients with active disease. In two
patients with normal conventional radiology,
positive monoclonal antibody scans were obtained
which located sites of disease recurrence, confirmed
by surgical lymphadenectomy. Conversely, in one
patient who had a normal antibody scan together
with abnormal conventional radiology, a congenital
G.I. cyst was found at operation. Therefore, this
method appears to be useful in the assessment of
disease status in patients with PLAP-positive
neoplasms.
Antibody guided irradiation - Fact or fiction
S. Stewart & A.A. Epenetos
On behalfofthe Hammersmith Oncology Group,
Royal Postgraduate Medical School, Hammersmith
Hospital and the Imperial Cancer Research Fund,
London, UK.
To maximise the therapeutic potential of mono-
clonal antibodies their administration into body
cavities has been explored.
Patients with advanced carcinoma of the ovary
were treated intraperitoneally with 131Iodine
labelled monoclonal antibody given singly or as a
mixture, depending on immunohistochemistry.
Symptomatic benefit was observed in most cases.
Four out of six patients with Stage III disease
have achieved complete remission at two years
following therapy. Toxicity was noted if more
than 100mCi of radioactivity was administered
(i.e. reversible diarrhoea, leucopenia and thrombo-
cytopenia).
Patients with pleural and/or pericardial effusions
of diverse neoplastic aetiology have been treatedACP 1st ANNUAL MEETING 215
with local instillation of monoclonal antibody. (20-
100mCi 1311). Ten out of thirteen patients achieved
remission. This treatment appears to be effective in
terms of alleviating fluid reaccumulation.
Monoclonal antibody (EGFRl) against epidermal
growth factor receptor has been used to treat five
patients with Grade III or IV gliomas. Three
patients showed significant symptomatic improve-
ment with this therapy.
These three areas are now being explored in
prospective studies to determine the clinical value
of monoclonal antibody therapy.
Radioimmunotherapy of colorectal cancer
R.H. Begent1, J.A. Ledermann1, K.D. Bagshawel,
F. Searle', P.A. Keep1, A.J. Green', R.G. Dale2
& M.G. Glaser3
'Department ofMedical Oncology, 2Department of
Medical Physics and 3Department ofRadiotherapy,
Charing Cross Hospital, London W6, UK.
Antibodies directed against carcinoembryonic
antigen (CEA) will localise in colorectal cancer
when given intravenously. They can be labelled
with 131lIodine (1311) to deliver therapeutic doses of
radiation. However, much of the radiolabelled
antibody persists in normal tissues giving them an
unacceptable dose. Imaging doses of radiolabelled
(first) antibody to CEA can be cleared from normal
tissues by giving a second antibody directed against
the first. The purpose of this study was to
investigate whether second antibody could be used
to improve the therapeutic ratio of radioimmuno-
therapy with therapeutic doses of radiolabelled
antibody. Five patients with unresectable colorectal
cancer were given 2.5mg of goat anti-CEA labelled
with 40-55mCi 1311. Twenty-four hours later 7.5mg
of horse anti-goat second antibody was given.
Clearance of first antibody was accelerated by
second antibody in 4/5 as shown by falling levels of
radioactivity in the blood and by gamma camera
imaging. Radioactivity was cleared in the urine and
a smaller amount in the faeces. Radioactivity was
retained in the tumours in all patients and in one,
pain relief and reduction in serum tumour marker
levels was noted. One patient had a transient fever
and another a rigor. There was no other ioxicity.
This forms a basis for a dose escalation study to
determine whether a useful antitumour effect can be
achieved.
Endometrial stromal sarcoma- Response to
medroxyprogesterone after danazol treatment
D. Parker
Oncology Unit, Bradford Royal Infirmary, Bradford
BD9 6JR, UK.
Endometrial stromal sarcoma is an unusual tumour
whose histological appearance may belie its
aggressive behaviour.
A 37-year old patient is described who developed
invasion of the vagina and bladder with bilateral
hydronephrosis four years after hysterectomy. The
histology of the uterus had shown 'stromal myosis'.
Further histological specimens had shown no clear
evidence of malignancy until sections of the bladder
wall were examined after hydronephrosis had
developed.
The tumour had progressed in the face of
danazol 200mg daily for 10 months and tamoxifen
20mgbd for 2 months. Medroxyprogesterone
100mg daily resulted in haematuria followed by
gradual resolution of her symptoms. There was
objective evidence of tumour regression on CT scan
and some improvement in renal function.
This case illustrates the importance of positive
diagnosis of endometrial stromal sarcoma. The
contrast between progression on danazol and
regression on progestogens is important in view of
the use of danazol for endometriosis. Patients with
rare but responsive tumours are a significant group.
Phase II trial of carboplatin (JM8) in the treatment
of patients with mesothelioma (M)
E.K. Mbidde, I.E. Smith & S. Harland
Lung Unit, Department ofMedicine, Royal Marsden
Hospital, Downs Road, Sutton, Surrey, SM2 5PT,
UK.
Carboplatin (JM8) is a new cis-platin analogue with
a similar spectrum of clinical activity to the parent
compound but without nephrotoxicity or neuro-
toxicity, and with better patient tolerance. In this
phase II study the activity of JM8 was assessed
against mesothelioma (M), for which conventional
treatment is usually ineffective. Seventeen patients
(pts) with symptomatic M (13 pleural, 4 peritoneal)
were treated with JM8 300-400mgm-2 i.v. q. 28
days. Fourteen were males and 3 females, median
age was 57 (range 22-78yrs). All pts had evaluable
disease on chest X-ray, CT scan or had measurable
subcutaneous nodules, and were staged according
to the modified schema of Butchart (Antman, K.H.
Sem. Oncol.,8,313, 1981). Threepatientshadstage(S)216 ACP 1st ANNUAL MEETING
I disease, 8 pts SIT, 4 pts Sll and 2 pts SIV. Prior
therapy included chemotherapy in 3 pts and radio-
therapy in 4 pts. One patient with peritoneal SI
achieved a CR (15 months duration) and 1 pt with
pleural SII achieved a PR (11 months duration),
(overall response rate 2/17; 12%; 95% confidence
limits 0-27%). Four other pts with pleural M
(24%) had marked symptomatic relief of pain or
dyspnoea lasting 1, 3+, 4 and 14 months. All pts
who achieved either an objective or a subjective
response were previously untreated. All responses
or relief of symptoms began to occur within 2
courses of treatment. In general therapy was well
tolerated. Toxicity (WHO Grade) was as follows:
Nausea/vomiting grade I 5 pts, II 7 pts, III 1 pt;
leucopenia I-II 0 pts, III 1 pt; thrombocytopenia I
1 pt; anaemia II 1 pt. JM8, like other cytotoxic
drugs, is active only in a small minority of pts with
mesothelioma but its low toxicity and ability to
achieve symptomatic relief may justify a therapeutic
trial of up to 2 courses, with further treatment
reserved for patients achieving clinical benefit.
Phase II studies of a novel antifolate CB3717, and
the platinum analogues JM8 and JM9, in
mesothelioma of pleura and peritoneum
B.M.J. Cantwell, A.L. Harris & S. Ghani
University Department ofClinical Oncology,
Regional Radiotherapy Centre, Newcastle General
Hospital, Newcastle upon Tyne, UK.
The objective response rate of malignant meso-
thelioma to cytotoxic chemotherapy is low and
'standard' chemotherapy does not exist. We treated
18 patients with inoperable progressive meso-
theliomas (17 pleural, 1 peritoneal) with CB3717
(an inhibitor ofthymidylate synthetase) i.v. 3 weekly
as first systemic treatment. One patient had an
objective partial response. CB3717 toxicities
included reversible hepatoxicity (transaminitis),
nausea, lassitude, skin rashes, conjunctivitis and
one hypersensitivity-type reaction.
Thirteen patients were given platinum analogues,
8 receiving JM8 and 5 JM9 as part of a
multinational phase II comparative study. Two of 8
JM8 treated patients had prior CB3717, 3 of 5 JM9
treated patients had prior CB3737. In 8 JM8
treated patients 2 objective partial responses
occurred (one patient previously responded to
CB3717). Toxicities of JM8 and JM9 were similar:
emesis in first 24h, myelosuppression and diarrhoea
in some JM9 treated patients. Both drugs were
easily administered by i.v. infusion once monthly on
an out-patient basis. JM8 emerges as active in
mesothelioma and study continues. Primary.drug
resistance is a major obstacle to successful
treatment of mesothelioma and phase II studies of
novel agents should be first line treatment.
Drug doses in these studies were: CB3717 300-
400mgm-2; JM8 400 mgm-2; JM9 300 mgm-2,
with dose modifications for toxicity. Patients
received a maximum of 6 courses of any drug.
High-dose ifosfamide in small cell lung cancer
H.M. Warenius1, D.C. Hurman2 & B. Cottier2
1Liverpool University Department ofRadiation
Oncology, Clatterbridge Hospital and 2Mersey
Regional Centrefor Radiotherapy and Oncology,
Clatterbridge Hospital, Bebington, Wirral, L63 4JY,
UK.
Nineteen previously untreated patients with either
limited-disease (LD-SCLC) or extensive-disease
small cell lung cancer (ED-SCLC) received single-
agent high dose (HD) ifosfamide (8gmm-2) as a
24h infusion with concurrent administration of
mesna. This treatment cycle was repeated at an
interval of 28 days.
Haematological toxicity was minimal with
neutropenic septicaemia occurring in only 1 patient.
Mesna was effective in preventing urothelial
toxicity.
Following 2 cycles of HD-ifosfamide, in 17
radiologically evaluable patients, there were 2
complete responses (CR) and 11 partial responses
(PR) giving an overall response rate (CR+PR) of
76.5%. Previous series have reported only a 50-
60% overall response rate (Souhami, Practitioner,
227, 1553, 1983; Aisner Proc 13th Int Cong.
Chemother. Vienna, 228, 19, 1983) to conventional-
dose ifosfamide.
Our results represent a significant improvement
in response rate, indicating a possible dose-response
relationship for ifosfamide in the treatment of
SCLC.
Serum CA 125 and CA 153 as tumour markers in
clinical practice
K. Patel', D. Parker', P. Harnden-Mayor2
& B. Naylor2
1Department ofMedical Oncology and 2Department
ofPathology, Bradford Royal Infirmary, Bradford
BD9 6RJ, UK.
Our experience of CA 125 as an ovarian tumour
marker at Bradford Royal Infirmary is presented.ACP 1st ANNUAL MEETING 217
A total of 56 patients including 36 with ovarian
cancer were followed up. Six of 7 (85%) patients
with measurable tumour bulk had a positive
correlation between serum CA 125 level and
tumour response. In 6/20 (30%) of patients with
non-ovarian malignancy elevated levels of CA 125
were found. Concurrent assay of CA 153 dis-
criminated between breast and ovarian carcinoma
in 27/28 patients. CA 125 appears a reliable
marker for ovarian carcinoma. The ratio between
CA 125/CA 153 levels allows discrimination
between breast and ovarian carcinoma. The mini-
mum detectable tumour bulk with these markers
remains to be established.
The radiological contribution to the staging of
anaplastic testicular germ cell tumours (AGCT):
Does lymphography have a role?
S.M. Crawford', B.K. Wignall2, J.E. Boultbee2,
J. Mclvor2, J.A. Ledermann', E.S. Newlands'
& R.H.J. Begent'
Departments of 'Medical Oncology and 2Diagnostic
Radiology2, Charing Cross Hospital, London W6
8RF, UK.
Accurate staging is essential in the management of
AGCT, especially when a surveillance-only policy
for Stage I tumours is pursued. Traditionally this
has included computed tomography (CT) and
lymphography (LG). LG is a time-consuming and
uncomfortable procedure. We have assessed its
diagnostic yield in comparison with that of CT in
respect of para-aortic lymphadenopathy (PAL).
The radiological records were reviewed of 38
patients in whom CT had been performed at
Charing Cross Hospital and who had LG either
performed or reviewed here. In 2 of 5 patients with
a positive CT, the LG was negative. Of 33 in whom
CT was negative, the LG confirmed PAL in only 1.
When tumour markers are taken into account, no
patient's management was altered by LG.
In patients assigned to Stage I follow-up, the
relapse rate among those who had had LG was
29% compared with 9% among those who had not
(X2 =2.64, NS).
Ultrasound is highly concordant with CT in
assessing PAL and is much more sensitive in
detecting liver metastases. We suggest that it, rather
than LG, is the investigation of choice to
complement CT.
Gastric cancer: Prognostic indicator of survival
D. Cunningham', D. Hole3, D.J. Taggart2,
D.C. Carter2, M. Soukopl & C.S. McArdle2
'Department ofMedical Oncology and 2University
Department ofSurgery, Glasgow Royal Infirmary
and 3the Cancer Surveillance Unit, Ruchill Hospital,
Glasgow, UK.
We have reviewed the records of 328 cases of
gastric cancer treated in the Royal Infirmary,
Glasgow between January 1974 and December
1984. Of these patients, 128 (39%) had a curative
resection (CR), 32 (9.8%) had a palliative resection
(PR), 33 (10.0%) had a gastroenterostomy (G), 26
(7.9%) had a celestin tube inserted (CT), 58 (17.7%)
had a laparotomy alone (LA) and 51 (15.5%) had
no surgical procedure (NS). Operative mortality for
the CR group has dropped from 17.6% between
1974-79 to 8.4% between 1980-84.
The 5 year survival (YSu) for all patients was
11%, but all long term survivors (except 1 patient)
came from the CR group who had a 5YSu of 24%.
The best predictor of long term survival for the CR
group was serosal involvement (P<0.001).
Also, patients with a long duration of symptoms
(>6 months) survived longer (5YSu=51%) than
those with a short history (<6 months; 5YSu=
14%) P=0.001. Of the patients who did not have
a curative procedure: the median survival for the
PR group was 6 months which was significantly
better (P<0.05) than the survival of the groups;
G 4 months, CT 2 months, LA 2 months and NS
1 month.
This analysis defines the prognostic indicators for
survival of patients with gastric cancer. A subgroup
of patients with a long duration of presenting
symptoms, who ultimately have a good prognosis,
has been identified and these findings may reflect
an intrinsic difference in 'tumour biology'.
Six drug alternating combination chemotherapy in
the treatment of poor prognosis non-Hodgkin's
lymphoma
J.A. Green
CRC Department ofRadiation Oncology,
Clatterbridge Hospital, Wirral, Merseyside, L63
4JY, UK.
There have been several reports of attempts to
improve the response rate and survival in non-
Hodgkin's lymphomas of aggressive histological218 ACP 1st ANNUAL MEETING
type by dose escalation, increase in number of
drugs or schedule manipulation. Etoposide has
recently been shown to be active in this tumour and
had been incorporated in an intensive 6 drug
regime. Twenty-two patients were treated with
adriamycin 5Omgm-2 i.v. vincristine 1.4 mgm 2
day 1, methotrexate 300mgm-2 days 7, 14, 28, 35,
cyclophosphamide 600mgm-2 i.v. day 21,
etoposide 12Omgm-2 i.v. days 21-23, and
prednisolone 60mgm-2 oral days 1-5 and 21-25.
The mean age was 48 (range 29-71), and the stages
were I: 2, II: 13, III: 3, IV: 4. Two patients had
received prior radiotherapy and none previous
chemotherapy. Consolidation radiotherapy was
given to sites of bulk disease in 3 patients. A total
of 4 course (24 weeks) was planned and 15 patients
received this number. Toxicity was acceptable with
one patient transferred to an alternative regime
after 1 cycle, 6 episodes of neutropenic fever and
no toxic deaths. Of 19 evaluable patients, there
have been 15 complete remissions and 4 partial
remissions. Three patients have died, at 3 months
(mesenteric artery thrombosis), and 2 at 9 months
(relapsed disease resistant to second-line treatment).
Median follow-up is 1 year with 5 patients alive
and well at over 2 years. The high response rate of
this combination with acceptable toxicity is
encouraging.
Methyl prednisolone, VP16, vindesine and
chlorambucil (PEEC) as initial or salvage therapy for
non-Hodgkin's lymphoma (NHL)
R.C.F. Leonard and S.J. Proctor on behalf of the
East of Scotland and Newcastle Lymphoma
(ESNLG) Working Party on Therapy (J.S. Scott,
N.C. Allan, A. Parker, A. Dawson, G. Ritchie, T.
Sarkar, R. Prescott, H. Lucraft & A. Harris)
We have recently completed a pilot study of a novel
combination of drugs, PEEC, (P 500mgm 2; VP16
100mgm-2 i.v.; vindesine 3mgm-2 i.v.;
chlorambucil 30mgm2 p.o. day 1; VP16
200mgm-2; chlorambucil 30mgm-2 days 2 and 3
repeat xq 3/52) with the aim of identifying an active
and acceptably toxic regime with potential as
salvage therapy or for alternating with CHOP-like
combinations in the initial treatment of advanced
high grade (HG) NHL. Thirty-two patients (pts),
19 at Newcastle and 13 at Edinburgh, were given
PEEC or PEEC-CHOP as initial therapy (IT, 23
pts) or salvage (S, 9 pts). Twenty-six of 32 had HG
pathology and 1 stage IE (B) 5 stage II, 10 stage III
and 16 stage IV; 18 had B symptoms. All pts are
included in the analysis of activity and toxicity. For
PEEC alone (11 pts) the objective response (OR)
was 64% (27% CR) whereas for PEEC-CHOP the
OR was 71% (52% CR). Analysis of IT pts alone
shows 6/7 OR for PEEC and 15/16 OR (69% CR)
for PEEC/CHOP. Toxicity for PEEC was mainly
alopecia 9 WHO grade III) with minor myelo-
toxicity and grade I/II nausea and vomiting.
Toxicity for PEEC/CHOP was conveyed mainly by
CHOP. Follow-up is early for survival analysis. The
promising activity of PEEC/CHOP for HGNHL
has initiated a multi-centre (ESNLG) phase III trial
comparing the strategy of alternating the
combination with bleomycin (B) and methotrexate
(M) (i.e. CHOP-M/PEEC-M) with B CHOP M
alone and early salvage PEEC-M.
Evidence of chronic bone marrow damage in patients
treated with MVPP for Hodgkin's disease
J.A. Radford', N.G. Testa2 T.M. Dexter2
& D. Crowther1
Departments of 'Medical Oncology & 2Experimental
Haematology, Christie Hospital & Paterson
Laboratories, Wilmslow Road, Manchester, UK.
Acute myelosuppression is a common cause of
treatment delay or curtailment in patients
undergoing chemotherapy for malignant disease.
Bone marrow (BM) regeneration quickly restores a
picture of apparent normality once treatment is
complete but evidence of persisting BM damage can
be found co-existing with a normal blood picture,
both in experimental systems and in patients (Testa
et al., Anticancer Res., 5, 101, 1985). The BM of
patients in complete remission from Hodgkin's
disease (HD) with a normal peripheral blood count
and at least one year after the completion of MVPP
therapy have been compared with two groups of
controls (BM from surgically excised ribs and from
patients with HD at diagnosis) using the technique
of long term bone marrow culture in vitro.
Differences have been observed between the treated
group and controls in both the morphology of the
stromal cell adherent layer and in the production
of haemopoietic progenitor cells (granulocyte
macrophage colony forming cells, GM-CFC) with a
marked reduction in the MVPP treated group.
These results suggest chronic BM damage in the
treated individuals, and experiments are in progress
to determine the relative involvement of stem cells
and the supporting stroma.ACP 1st ANNUAL MEETING 219
New bone formation seen during chemotherapy
G.J. Forrest', N.L. Gilchrist', B. Boyce2,
D. Cunningham', I.T. Boyle3 & M. Soukop1
'Department ofMedical Oncology, 2Department of
Pathology and 3Department ofPathology, Royal
Infirmary, Glasgow G4 OSF, UK.
Combination chemotherapy is known to affect the
growth rate of several human tissues. Six patients
undergoing chemotherapy for Hodgkin's Disease
(HD) were investigated to see whether the
administration of combined chemotherapy affected
the rate of new bone formation. Patients received a
bone biopsy prior to the start of therapy and after
six pulses of chemotherapy with mustine 6mgm-2,
vincristine 1.4mgm-2, hydrocortisone 100mg, all
given on days 1 and 8 with procarbazine 100mg
and prednisolone 40mg given daily by mouth days
1-14, cycled every 6 weeks. Only one patient
showed bone involvement with HD prior to
therapy. Four patients showed marked osteopaenia
with decreased bone trabeculae prior to therapy.
After six pulses of chemotherapy it was found the
four patients with marked osteopaenia previously,
had shown marked new bone formation during the
period of treatment. No change in bone formation
was found in the other two patients. No change in
any biochemical marker could be found between
pre and post treatment values. These results are
contrary to what might have been expected and the
cause of this phenomenon is not known, but may
be due to local hormonal activity within bone.
A new marker of disease for malignant lymphoma
B.W. Hancock1, L. Bruce1, L. Cawood1
& S. Metcalfe2
1Department ofMedicine, Royal Hallamshire
Hospital, Sheffield and 2Department ofSurgery,
Addenbrooke's Hospital, Cambridge, UK.
Patients with malignant lymphoma - 144 with non-
Hodgkin's lymphoma (NHL) and 132 with
Hodgkin's disease (HD) - have been monitored by
both erythrocyte sedimentation rate (ESR) and the
B5 test, in addition to standard clinical and
radiological assessments. The B5 test involves
haemagglutination by a monoclonal antibody
designated B5 (Metcalfe et al., Br. J. Cancer, 49,
337, 1984).
Of those patients who were well and in remission,
41/155 (26%) showed some B5 positivity: this
compared to an incidence of 20% in non-tumour
bearing individuals (122/551). In contrast, those
patients with persistent active disease, or in relapse,
showed a much higher incidence of B5 positivity
(84%, 99/118).
Combination of ESR and B5 gave an increased
specificity for active disease in that 35/40 (87%) of
patients who were B5 positive and had a raised
ESR, also had active disease; marker negative
patients with a normal ESR rarely showed active
disease (9/180; 8%).
Serial monitoring of 113 patients showed that B5
status often followed tumour status, becoming
negative in remission. Overall, B5 used in
combination with ESR improved both the
specificity and sensitivity of monitoring malignant
lymphoma over that of either test alone. These
findings suggest a role for the B5 test to be
included in the clinical monitoring of HD and
NHL patients.
Intermediate lymphocytic lymphoma - A possible
origin in mucosa associated lymphoid tissue
P.A. Daly, D.S. O'Briain, F. Rogers, E. Lawlor,
C. Blaney & A.J. O'Brien
Departments ofClinical Haematology-Oncology and
Histopathol, St James's Hospital and Trinity
College, Dublin 8, Eire
Sevenpatientswithmalignantlymphomalymphocytic
of intermediate-cell type (ILL) were studied over
4 yrs. Three patients presented with gastrointestinal
(GIT) disease and 2 with disease of the urinary
bladder. One of the latter had extensive GIT disease
which was asymptomatic and a further patient had
radiological evidencc of disease in the terminal
ileum. The remaining patient had a solitary extra-
nodal lesion above the rt. breast which developed
during pregnancy. There were 5 males and 2
females, age range 33-60yrs - median 46. Three
patients with GIT involvement fulfilled the criteria
for multiple lymphomatous polyposis (MLP) of the
GIT. Other sites of involvement included
abdominal and peripheral lymph nodes, bone
marrow, peripheral blood, spleen, liver, lung and
meninges. The histology was diffuse in 3 and
follicular in 4 where the growth pattern was of a
mantle zone lymphoma. An 8th pt, male, aged 71
years, with MLP had the histologic picture of
poorly differentiated lymphocytic lymphoma
(PDLL) diffuse, but had an immunologic pheno-
type which was similar to that found in patients
with ILL. Immunohistochemistry on cryostat
sections from 5 pts showed strong monotypic Ig
staining, HLADR+ve., B1+ve., T1O-ve and220 ACP 1st ANNUAL MEETING
variable reaction with CALLA, Ti and FMC7.
Peripheral blood of 4 patients also showed a B-cell
clonal expansion (Bl +ve., SmIg+ve., HLA
DR+ve., FMC7+ve). Involvement of mucosal
surfaces, especially the GIT and urinary tract, is
common in this lymphoma with a distinctive
histology and immunologic phenotype suggesting a
possible origin in mucosa associated lymphoid
tissue (MALT). This should be taken into con-
sideration when staging patients with this particular
non-Hodgkin's lymphoma because of the obvious
therapeutic implications and further studies should
help to clarify the mucosal immunologic system.
Incidence and tramission of human T-cell leukaemia
lymphoma virus (HTLV-1) in the UK
A.G. Dalgleishl, E. Matutes2, D. Catovsky2,
R.A. Weiss', T.A. Lister2, S. Pegram4
& M.F. Greaves4
'Institute ofCancer Research Fulham Road, London
SW3 6JB, 2MRC Leukaemia Unit, Royal
Postgraduate Medical School, Hammersmith
Hospital, London W12, 3St Bartholomew's Hospital,
London EC2 and 4Leukaemia Research Fund
(Institute ofCancer Research), UK.
HTLV-1 is the causative agent of adult T-cell
leukaemia/lymphoma (ATLL) which was first
recognised in the UK as occurring in people of
Caribbean origin (Lancet, i, 639, 1982), an
observation which led to the recognition that the
Caribbean basin, like Japan, was endemic for
HTLV-1 infection.
We have screend over 500 sera from communities
with large Caribbean immigrant community and
found 19 seropositive asymptomatic petple. Studies
on the family members have revealed marked
clustering within families. In one case a husband
and wife and 2 eldest children (over 20 years) were
seropositive whilst their youngest 2 children were
seronegative. Both the seropositive children were
born in the UK and one had never been abroad.
Following short term lymphocyte culture, virus was
detected by specific monoclonal antibodies to
HTLV-1 (p19 and p24) and by electron microscopy
in 4 of the healthy seropositive people. These data
support that HTLV-1 has a very low incidence in
the UK, outside the Caribbean Community, as well
as that the most likely modes of transmission in
this country is sexual, blood to blood and mother
to child.
Two cases of HTLV-1 antibody positive ATL in
white Caucasians in the UK with no known con-
tacts or risk factors suggest that white Caucasians
may be more susceptible to HTLV-1 infection and
have a short mean incubation time to the develop-
ment of ATLL compared with Japanese and
Afro-Caribbean peoples. Other unreported cases
support this hypothesis (R.C. Gallo, personal
communication).
Prognostic indicators in patients with high grade
histology non-Hodgkin's lymphoma receiving VAP
R.A. Cowan', J.M. Jones2 & D. Crowther'
'CRC Department ofMedical Oncology and
2Department ofMedical Statistics, Christie Hospital
& Holt Radium Institute, Manchester M20 9BX,
UK.
We have studied 200 patients with high grade non-
Hodgkin's lymphoma treated by the Manchester
Lymphoma Group between 1975 and 1985 to
ascertain which factors are useful in predicting
disease outcome. The cohort comprises patients
with localised and widespread disease and all have
been treated in protocols incorporating weekly
chemotherapy with VAP (vincristine, adriamycin,
prednisolone). The median follow-up for the group
is 52 years.
Prognostic variables have been examined using
the logrank test and multivariate analyses
(discriminant method and Cox's model).
Factors independently associated with an
improved overall survival were: attainment of
complete remission (CR), P= <0.000001, a serum
LDH within the normal range, P=0.0005, clinical
stage I disease, P=0.018 and centroblastic
histology (Liel classification), P=0.034. Excluding
remission status from the analysis, clinical stage
became the most important indicator of prognosis,
P= <0.0001, followed by serum albumin, patient
age and Gamma GT. Having shown attainment of
CR to be so important in determining survival,
discriminant analysis was performed to ascertain
which factors predicted the likelihood of achieving
CR: clinical stage and serum albumin were equally
important followed by B symptoms and bulk
disease. Multivariate analysis was also carried out
to assess which factors were predictive of survival
in patients who had achieved CR and this revealed
clinical stage, Gamma GT and centroblastic
histology to be significant.
These results concur with other smaller published
series and it is hoped that such prognostic infor-
mation will prove useful in selcting which patients
should be treated with the more intensive chemo-
therapy currently advocated for high grade non-
Hodgkin's lymphoma.ACP 1st ANNUAL MEETING
N-acetyl-b-d-glucosaminidase (B NAG) as an early
marker of cis-platin-induced renal tubular dysfunction
M. Teeling', B. Casey2, I. Pratt2, M. Ryan2
& D.N. Carney'
'Medical Oncology Unit, Mater Hospital, Dublin 7
and 2Department ofPharmacology, UCD, Eire
The long term use of the cytotoxic agent cis-platin
(P) is limited by its nephrotoxicity. To assess its
value as an early marker of renal tubular
dysfunction sequential urinary levels of the
lysosomal enzyme B NAG were measured in 20
patients receiving P chemotherapy (CT) for a
variety of malignancies. Levels of B NAG were
measured in pre and post treatment urine samples
and compared with urinary excretion of magnesium
(Mg), plasma Mg and standard parameters of renal
function. Following P treatment, a marked
elevation in B NAG excretion was seen in all
patients, reaching a peak level between 1-5 days
post treatment, and returning to base line levels by
7-9 days. Greater levels of B NAG excretion were
seen in the first course of CT than in subsequent
courses, while plasma creatinine and urea values
remained within the normal range. Urinary
excretion of Mg was within the normal range
during the first course of CT but Mg wasting was
frequently seen in later courses of CT, associated
with hypomagnesaemia. Persistently elevated levels
of B NAG were observed in one patient who later
developed renal insufficiency. Peak excretions of
B NAG were dissociated in time from maximum Mg
excretion. These results suggest; (1) Urinary
excretion of B NAG is a sensitive indicator of P
nephrotoxicity, (2) Persistently elevated urinary
excretion of B NAG predicts for early renal
dysfunction and (3) the dissociation in time of Mg
wasting from B NAG excretion may not be directly
related to the P-induced proximal tubular damage.
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